Infant Bacterial Therapeutics AB (publ)

SSE:IBT-B.ST

93.4 (SEK) • At close February 20, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) SEK.

2024 Q22024 Q12023 Q42023 Q32023 Q22023 Q12022 Q42022 Q32022 Q22022 Q12021 Q42021 Q32021 Q22021 Q12020 Q42020 Q32020 Q22020 Q12019 Q42019 Q32019 Q22019 Q12018 Q42018 Q32018 Q22018 Q12017 Q42017 Q32017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q42015 Q32015 Q22015 Q1
Revenue 00.00500.06400.0130.0090000000000000000000000.1210.1170.1130.049000000
Cost of Revenue 00000000000000000000000000000000000000
Gross Profit 00.00500.06400.0130.0090000000000000000000000.1210.1170.1130.049000000
Gross Profit Ratio 01010110000000000000000000001111000000
Reseach & Development Expenses 36.68527.89247.88231.06830.0921.5340.7667.746-1.75819.06616.093-0.22829.195-0.38826.70318.66527.994-1.13127.42611.0077.9230.92923.8767.683-1.2869.1449.0594.57113.9478.6814.22510.49210.9755.1034.1514.1514.8374.837
General & Administrative Expenses 7.5941.917.1572.7140.8622.77900000000000000000000000000000.2460.24600
Selling & Marketing Expenses 00000000000000000000000000000002.543001.31.300
SG&A 7.5941.917.1572.7140.8622.7791.0170001.1150001.1360001.2350001.0860000.9570000.8342.543001.5461.54600
Other Expenses 00000-0.013-0.00900-0.00300-0.031-0.064-0.079-0.079-0.079-0.0750000000000000-2.543000000
Operating Expenses 44.27929.79755.03933.71830.95224.29640.7577.746-1.75819.06316.093-0.22829.164-0.45226.62418.58627.915-1.20627.42611.0077.9230.92923.8767.683-1.2869.1449.0594.57113.9478.6814.2257.94910.9755.1034.834.834.8374.837
Operating Income -44.279-29.798-55.039-33.718-30.952-24.296-40.757-7.7461.758-19.063-16.0930.228-29.1640.452-26.624-18.586-27.9151.206-27.426-11.007-7.923-0.929-23.876-7.6831.286-9.144-9.059-4.571-13.826-8.563-14.112-7.9-10.975-5.103-5.471-5.471-4.837-4.837
Operating Income Ratio 0-5,959.60-526.8440-1,868.923-4,528.556000000000000000000000-114.264-73.188-124.885-161.224000000
Total Other Income Expenses Net 1.6041.98414.1482.8292.1321.8270.641-0.036-0.11-0.138-0.125-0.286-0.001-0.001-0.024-0.014-0.022-0.028-0.1080.4690.3620.243-0.267-0.302-0.62100-0.015-0.00100.0070.1830-0.06210.310.3-0.004-0.004
Income Before Tax -42.675-27.814-40.891-30.889-28.82-22.469-40.116-7.7821.648-19.201-16.218-0.058-29.1650.451-26.648-18.6-27.9371.178-27.534-10.538-7.561-0.686-24.143-7.9850.665-9.144-9.059-4.586-13.827-8.563-14.105-7.717-10.975-5.1654.8294.829-4.84-4.84
Income Before Tax Ratio 0-5,562.80-482.6410-1,728.385-4,457.333000000000000000000000-114.273-73.188-124.823-157.49000000
Income Tax Expense 1.6041.985-0.2042.8282.132-0.001-0.6410.0360.110.1380.1250000.0410.0580.0580.0580.0260.6380.5460.4810.1570.170000000-7.9-10.975-0.06210.310.3-0.004-0.004
Net Income -42.675-27.815-40.891-30.888-28.82-22.468-39.475-7.8181.648-19.339-16.218-0.058-29.1650.451-26.648-18.6-27.9371.178-27.534-10.538-7.561-0.686-24.143-7.9850.665-9.144-9.059-4.586-13.827-8.563-14.105-7.717-10.975-5.1654.8294.829-4.84-4.84
Net Income Ratio 0-5,5630-482.6250-1,728.308-4,386.111000000000000000000000-114.273-73.188-124.823-157.49000000
EPS -3.17-2.06-3.04-2.31-2.57-2-3.52-0.70.15-1.72-1.44-0.005-2.60.04-2.37-1.66-2.490.1-2.45-0.94-0.67-0.061-2.15-0.710.059-0.96-1.54-0.78-2.51-1.56-2.3-1.25-2.51-2.822.662.66-2.7-2.7
EPS Diluted -3.17-2.06-3.04-2.31-2.57-2-3.52-0.70.15-1.72-1.44-0.005-2.60.04-2.37-1.66-2.490.1-2.45-0.94-0.67-0.061-2.15-0.710.059-0.96-1.47-0.78-2.51-1.56-2.29-1.25-2.51-2.822.662.66-2.7-2.7
EBITDA -42.471-27.61-55.039-30.685-28.616-22.265-39.903-7.5421.962-18.859-15.8890.432-28.960.656-26.379-18.324-27.6531.468-27.196-10.165-7.173-0.244-23.515-7.3091.49-8.94-8.855-4.367-13.622-8.359-13.301-7.9-10.975-0.06210.310.3-0.004-0.004
EBITDA Ratio 0-5,5220-479.4530-1,712.692-4,433.667000000000000000000000-112.579-71.444-117.708-161.224000000